Goldman Sachs Reveals New 160% Opportunity

Income & Prosperity Investing Research
by 

Goldman Sachs (NYSE: GS) says…

Regenxbio Inc (NASDAQ: RGNX) could make you 160%.

Regenxbio is a biotechnology company that develops gene therapy treatments for genetic disorders.

Goldman just started coverage on the company because it’s optimistic about its gene therapy pipeline.

Regenxbio is working on gene therapies for eye conditions like wet AMD and diabetic retinopathy… as well as for Duchenne muscular dystrophy (DMD) and Hunter syndrome.

Even modest use of these therapies could lead to blockbuster sales, especially with the strong presence of partner AbbVie Inc (NYSE: ABBV) in ophthalmology.

Gene therapy stocks have recently underperformed due to economic factors and interest rates.

However, Goldman Sachs expects upcoming events to improve Regenxbio’s share performance in the near to intermediate term.

That’s why Goldman Sachs rates Regenxbio as a Buy with a price target of $38.

If they’re right, this means the stock could make you a 160% gain.

But while that’s a very good return…

I’m placing my bets in a much bigger profit opportunity in the AI boom.

One that could deliver 1,355% returns.

Here’s why.

The AI revolution is sparking a $2 trillion investment in new data centersaround the world.

But this massive growth is putting our power grid at risk – with frequent outages.

This is because we’re STILL using a power grid that was built in the 1960s and 1970s.

As Bill Gates says…

“We need [Hyper Power] if we’re going to meet the world’s growing need for energy while also eliminating carbon emissions. None of the clean sources are as reliable.”

Yours in Wealth,

Ian Wyatt

To top